| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/07/2011 | WO2011039445A1 Use of vanillin derivatives as a preservative, preservation method, compounds, and composition |
| 04/07/2011 | WO2011039444A2 Composition, use, and preservation method |
| 04/07/2011 | WO2011039379A1 Cooperative conveyance of basic active principles by amphiphilic acid molecules |
| 04/07/2011 | WO2011039259A2 Mucoadhesive polymers having vitamin b partial structures |
| 04/07/2011 | WO2011039147A1 Fluorocyclodextrins |
| 04/07/2011 | WO2011039096A1 Drug fusions and conjugates with extended half life |
| 04/07/2011 | WO2011018801A3 Solid oral dosage form of ziprasidone |
| 04/07/2011 | WO2011018227A3 Peptide libraries |
| 04/07/2011 | WO2011017055A3 Blood coagulation protein conjugates |
| 04/07/2011 | WO2011002077A8 TNF-α GENE THERAPY AGENT CONTAINED IN POLYMERIC MICELLE |
| 04/07/2011 | WO2010139752A3 Stabilised composition comprising at least one adrenergic compound |
| 04/07/2011 | WO2010139751A3 Stabilised composition comprising at least one adrenergic compound |
| 04/07/2011 | WO2010138395A3 Methods of treating chronic neurogenic inflammation using a modified clostridial toxin |
| 04/07/2011 | WO2010130728A3 Solid pharmaceutical preparations containing copolymers based on polyethers combined with poorly water-soluble polymers |
| 04/07/2011 | WO2010088527A3 Peptides and nanoparticles for therapeutic and diagnostic applications |
| 04/07/2011 | WO2010011585A3 Ophthalmic device having therapeutic agent delivery capability and method of forming same |
| 04/07/2011 | WO2009133408A3 Protein formulation |
| 04/07/2011 | US20110082482 Materials and Methods for Nerve Repair |
| 04/07/2011 | US20110082277 Modified bio-related substance, process for producing the same, and intermediate |
| 04/07/2011 | US20110082266 Therapeutic polymers and methods of generation |
| 04/07/2011 | US20110082221 In situ gelling systems as sustained delivery for front of eye |
| 04/07/2011 | US20110082220 Porcine umami taste receptors and uses therefor |
| 04/07/2011 | US20110082219 Thickeners |
| 04/07/2011 | US20110082214 Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet |
| 04/07/2011 | US20110082077 Sialic acid derivatives for protein derivatisation and conjugation |
| 04/07/2011 | US20110082076 Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| 04/07/2011 | US20110082071 Delivery system for an active ingredient |
| 04/07/2011 | US20110081415 Coating apparatus |
| 04/07/2011 | US20110081414 Method for Encapsulation of Orally Ingested Materials to Alter the Site of Digestion, Site of Action, or Stability |
| 04/07/2011 | US20110081412 Orally disintegrable tablets |
| 04/07/2011 | US20110081380 Stabilizing Excipient for Inactivated Whole Virus Vaccine |
| 04/07/2011 | US20110081366 Immunostimulatory nucleic acid molecules |
| 04/07/2011 | DE20321836U1 Hydroxyalkylstärkederivate Hydroxyalkylstärkederivate |
| 04/07/2011 | DE202009016292U1 Als Emulgator wirkende Zusammensetzung für wasserlösliche Solubilisate hydrophober Verbindungen Acting as an emulsifier composition of water-soluble solubilisates hydrophobic compounds |
| 04/07/2011 | DE10141652B4 Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung The transdermal therapeutic system based on polyacrylate pressure-sensitive adhesives having no functional groups and its use |
| 04/07/2011 | CA2776474A1 Topical tetracycline compositions |
| 04/07/2011 | CA2776366A1 Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| 04/07/2011 | CA2776271A1 Anti-hsv antibody |
| 04/07/2011 | CA2776198A1 Cooperative conveyance of basic active principles by amphiphilic acid molecules |
| 04/07/2011 | CA2776195A1 Hepatitis c virus vaccine composition |
| 04/07/2011 | CA2776141A1 Reduced-odor polyol composition and method of producing same |
| 04/07/2011 | CA2776022A1 Antibodies that specifically bind to the epha2 receptor |
| 04/07/2011 | CA2775890A1 Methods and compositions for deterring abuse |
| 04/07/2011 | CA2775833A1 Mucoadhesive polymers having vitamin b partialstructures |
| 04/07/2011 | CA2774559A1 Novel vaccine composition |
| 04/07/2011 | CA2774552A1 Drug fusions and conjugates with extended half life |
| 04/07/2011 | CA2768968A1 Positively-charged poly (d,l-lactide-co-glycolide) nanoparticles and fabrication methods of the same |
| 04/06/2011 | EP2305823A1 Materials and methods relating to protein aggregation in neurodegenerative disease |
| 04/06/2011 | EP2305819A1 Conjugates prepared with aggregate-free proteins |
| 04/06/2011 | EP2305804A1 MonoPEGylated human growth hormone |
| 04/06/2011 | EP2305794A1 Expansion of renewable stem cell populations |
| 04/06/2011 | EP2305722A1 Water-soluble acrylic acid salt polymer and gelling base |
| 04/06/2011 | EP2305716A2 Antibodies directed to gpnmb and uses thereof |
| 04/06/2011 | EP2305373A1 Microcapsule, process for production thereof, and food or beverage containing microcapsule |
| 04/06/2011 | EP2305314A2 Remodelling and glycoconjugation of antibodies |
| 04/06/2011 | EP2305313A2 Remodelling and glycoconjugation of interferon-alpha (IFNa) |
| 04/06/2011 | EP2305312A2 Remodelling and glycoconjugation of follicle-stimulating hormone (FSH) |
| 04/06/2011 | EP2305311A2 Glycoconjugation of peptides |
| 04/06/2011 | EP2305310A1 Gold -coated magnetic glyconanoparticles functionalised with proteins for use as diagnostic and therapeutic agents |
| 04/06/2011 | EP2305309A2 Conjugates for the administration of biologically active compounds |
| 04/06/2011 | EP2305308A1 Remedies for diseases to be applied to eye |
| 04/06/2011 | EP2305304A1 Immunopotentiating agent comprising ep1 agonist |
| 04/06/2011 | EP2305292A1 S/o type transdermal immunizing agent |
| 04/06/2011 | EP2305290A1 Salt-free composition comprising an intact Botulinum toxin complex |
| 04/06/2011 | EP2305288A2 Acidic insulin preparations with improved stability |
| 04/06/2011 | EP2305286A2 Treatment for Alzeimer's disease |
| 04/06/2011 | EP2305282A2 Prevention and treatment of amyloidogenic disease |
| 04/06/2011 | EP2305275A1 Liquid composition comprising cisplatin-coordinating compound |
| 04/06/2011 | EP2305272A1 Use of equol for treating skin diseases |
| 04/06/2011 | EP2305259A1 Novel substituted benzimidazole dosage forms and method of using same |
| 04/06/2011 | EP2305219A1 Pharmaceutical preparations coated with a copolyvidone-containing coating |
| 04/06/2011 | EP2305217A1 Method for the preparation of pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors |
| 04/06/2011 | EP2305215A1 Microemulsions of cannabinoid receptor binding compounds |
| 04/06/2011 | EP2305214A1 Novel molecular assembly, molecular probe for molecular imaging and molecular probe for drug delivery system using the same, and molecular imaging system and drug delivery system |
| 04/06/2011 | EP2305195A1 Drug delivery compositions for improved stability of steroids |
| 04/06/2011 | EP2304033A2 Functionalized polypeptides |
| 04/06/2011 | EP2304026A2 Nanoparticle compositions for nucleic acids delivery system |
| 04/06/2011 | EP2303948A1 Silica sol material having at least one therapeutically active substance for producing biologically degradable and/or resorbable silica gel materials for human medicine and/or medical technology |
| 04/06/2011 | EP2303929A1 A macrocyclic derivative and assemblies formed therefrom |
| 04/06/2011 | EP2303408A2 Pediculicide compositions |
| 04/06/2011 | EP2303337A1 Small molecule ligand-drug conjugates for targeted cancer therapy |
| 04/06/2011 | EP2303333A2 Conjugated vi saccharides |
| 04/06/2011 | EP2303332A2 Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| 04/06/2011 | EP2303331A2 Ophthalmic device having therapeutic agent delivery capability and method of forming same |
| 04/06/2011 | EP2303326A2 Treatment of solid tumors with tissue inhibitors of metalloproteinases (timps) |
| 04/06/2011 | EP2303288A2 Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases |
| 04/06/2011 | EP2303281A1 Transdermal pharmaceutical compositions comprising danazol |
| 04/06/2011 | EP2303279A1 Topical steroidal formulations |
| 04/06/2011 | EP2303265A2 Stable topical formulation comprising voriconazole |
| 04/06/2011 | EP2303243A1 Oral composition containing an anti-plaque agent of the thienopyridine family in the form of a base |
| 04/06/2011 | EP2303242A1 Pharmaceutical dosage form comprising polymeric carrier composition |
| 04/06/2011 | EP2303237A2 Preparation method of biodegradable micro-particles containing drugs |
| 04/06/2011 | EP2303236A2 Synergistic induction of humoral and cellular immunity by combinatorial activation of toll-like receptors |
| 04/06/2011 | EP2303233A1 Solid oral dosage form containing anti-platelet agent clopidogrel and method for the preparation thereof |
| 04/06/2011 | EP2303231A1 Preparation containing glucosamine and/or chondroitin for prophylaxis and treatment of arthrosis and for supporting the immune system |
| 04/06/2011 | EP2303230A2 Methods and compositions for enhanced delivery of macromolecules |
| 04/06/2011 | EP2303229A1 Concentrated oxaliplatin solution and its method of preparation |
| 04/06/2011 | EP2303227A2 Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
| 04/06/2011 | EP2303226A2 Sustained delivery of exenatide and other polypeptides |
| 04/06/2011 | EP2275089A9 Preparation of biodegradable microparticles containing a biologically active agent |